Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Aims - Fatigue is one of the most prominent side-effects of immune checkpoint inhibition. Therefore, we assessed the risk of fatigue associated with inhibitors of the immune checkpoints. - Materials and methods - We examined data from the Medline and Google Scholar databases. We also examined origin...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 June 2016
|
| In: |
Clinical oncology
Year: 2016, Volume: 28, Issue: 10, Pages: e127-e138 |
| ISSN: | 1433-2981 |
| DOI: | 10.1016/j.clon.2016.06.008 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clon.2016.06.008 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0936655516301261 
|
| Author Notes: | O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, A. Zidan, H. Oweira |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1725127687 | ||
| 003 | DE-627 | ||
| 005 | 20240406193241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200720s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clon.2016.06.008 |2 doi | |
| 035 | |a (DE-627)1725127687 | ||
| 035 | |a (DE-599)KXP1725127687 | ||
| 035 | |a (OCoLC)1341347023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Abdel-Rahman, Omar M. |e VerfasserIn |0 (DE-588)170878732 |0 (DE-627)06102290X |0 (DE-576)131722972 |4 aut | |
| 245 | 1 | 0 | |a Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors |b a systematic review and meta-analysis |c O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, A. Zidan, H. Oweira |
| 264 | 1 | |c 20 June 2016 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.07.2020 | ||
| 520 | |a Aims - Fatigue is one of the most prominent side-effects of immune checkpoint inhibition. Therefore, we assessed the risk of fatigue associated with inhibitors of the immune checkpoints. - Materials and methods - We examined data from the Medline and Google Scholar databases. We also examined original studies and review articles for cross-references. Eligible studies included randomised phase II and phase III trials of patients with cancer treated with ipilimumab, nivolumab, pembrolizumab and tremelimumab. The authors extracted relevant information on participants' characteristics, all-grade and high-grade fatigue and information on the methodology of the studies. - Results - In total, 17 trials were considered eligible for the meta-analysis. The odds ratio for all-grade fatigue for CTLA-4 inhibitors was 1.23 (95% confidence interval 1.07, 1.41; P = 0.003) and for high-grade fatigue was 1.72 (95% confidence interval 1.26, 2.33; P = 0.0005). Moreover, the odds ratio for all-grade fatigue for PD-1 inhibitors was 0.72 (95% confidence interval 0.62, 0.84; P < 0.0001) and for high-grade fatigue was 0.36 (95% confidence interval 0.23, 0.56; P < 0.00001). - Conclusions - The analysis of data showed that CTLA-4 inhibitors seem to be associated with a higher risk of all- and high-grade fatigue compared with control regimens, whereas PD-1 inhibitors seem to be associated with a lower risk of all- and high-grade fatigue compared with control regimens. | ||
| 650 | 4 | |a Fatigue | |
| 650 | 4 | |a ipilimumab | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 4 | |a tremelimumab | |
| 700 | 1 | |a Mehrabi, Arianeb |d 1967- |e VerfasserIn |0 (DE-588)137664583 |0 (DE-627)594829763 |0 (DE-576)304831263 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical oncology |d [Erscheinungsort nicht ermittelbar] : Saunders, 1989 |g 28(2016), 10, Seite e127-e138 |h Online-Ressource |w (DE-627)253721261 |w (DE-600)1458892-4 |w (DE-576)26186484X |x 1433-2981 |7 nnas |a Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors a systematic review and meta-analysis |
| 773 | 1 | 8 | |g volume:28 |g year:2016 |g number:10 |g pages:e127-e138 |g extent:12 |a Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors a systematic review and meta-analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clon.2016.06.008 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0936655516301261 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200720 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 137664583 |a Mehrabi, Arianeb |m 137664583:Mehrabi, Arianeb |d 910000 |d 910200 |e 910000PM137664583 |e 910200PM137664583 |k 0/910000/ |k 1/910000/910200/ |p 6 | ||
| 999 | |a KXP-PPN1725127687 |e 3725897069 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 20.07.2020"],"relHost":[{"origin":[{"publisherPlace":"[Erscheinungsort nicht ermittelbar] ; London ; Edinburgh","dateIssuedDisp":"1989-","dateIssuedKey":"1989","publisher":"Saunders ; Springer ; Harcourt"}],"id":{"eki":["253721261"],"zdb":["1458892-4"],"issn":["1433-2981"]},"part":{"issue":"10","year":"2016","extent":"12","text":"28(2016), 10, Seite e127-e138","volume":"28","pages":"e127-e138"},"recId":"253721261","disp":"Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors a systematic review and meta-analysisClinical oncology","title":[{"title_sort":"Clinical oncology","subtitle":"a journal of the Royal College of Radiologists","title":"Clinical oncology"}],"note":["Gesehen am 04.02.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1989 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"12 S."}],"language":["eng"],"title":[{"title_sort":"Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors","title":"Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors","subtitle":"a systematic review and meta-analysis"}],"person":[{"display":"Abdel-Rahman, Omar M.","role":"aut","given":"Omar M.","family":"Abdel-Rahman"},{"family":"Mehrabi","given":"Arianeb","role":"aut","display":"Mehrabi, Arianeb"}],"recId":"1725127687","name":{"displayForm":["O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, A. Zidan, H. Oweira"]},"origin":[{"dateIssuedDisp":"20 June 2016","dateIssuedKey":"2016"}],"id":{"doi":["10.1016/j.clon.2016.06.008"],"eki":["1725127687"]}} | ||
| SRT | |a ABDELRAHMATREATMENTA2020 | ||